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INTRODUCTION 
Liver fibrosis is one of the most widespread chronic 
liver diseases in the world. Fibrosis is the wound heal-
ing response of an organ and formation of fibrous scar 
tissue[1].During liver fibrosis there is an excessive pro-
duction and deposition of extracellular matrix protein
(ECM) including collagen which disrupts the normal 
structure of the liver and cause activation of hepatic 
stellate cells (HSCs)[2, 3].Nonalcoholic fatty liver diseas-
es (NAFLD), alcoholic liver diseases, chronic hepatitis B 
(HBV) and hepatitis C (HCV) are the most common 
causes of liver fibrosis[4, 5].  
Fibrosis is the first stage of liver cells scarring and later 
if more of the liver becomes scarred, it’s known as liver 
cirrhosis. A scar is a fibrous tissue made up of collagen 
that replaces the injured cells, performs no function, 
type I and type III are the types of collagen that 
makeup scar tissue.  Typically, a hepatic stellate cells 
(HSCs) play acentral role in the pathogenesis of hepatic 
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fibrosis and comprise 15% of the liver cell mass[6]. The 
activation of Cellular component primarily hepatic stel-
late cells is important during the initiation and develop-
ment of liver fibrosis[2]. Hepatic stellate cell stores vita-
min A as retinyl esters, due to the liver fibrosis HSCs 
proliferate, lose their vitamin A and undergo major 
phenotypical transformation to myofibroblast 
(activated HSCs) that increasingly express α-smooth 
muscle actin and  produces collagenous extracellular 
matrix proteins[7].The transforming growth factor-β1 
(TGF-β1) is a cytokine, important in hepatic stellate 
cells activation and proliferation and regulation of ECM 
formation[8].TGF-β1 is acted in an autocrine and para-
crine manner and is produced by kupffer cells[9]. 
Matrix metalloproteinase (MMP) have capability to 
degrade the ECM component. But in fibrotic liver there 
is an expression of tissue inhibitor of metalloproteinas-
es, which inhibit the MMP and play a key role in fibro-
genesis. Therefore, the inactivation of activated HSC is 
a key process for the recovery from liver fibrosis[1]. 
Fibrosis can occasionally reverse if the cause is identi-
fied rapidly. Fibrosis can develop because of continu-
ously damaging cells for month or year. Diosgenin has 
shown antioxidant, hypolipidaemic activity. This re-
search demonstrated that activity of herbal medicine 
diosgenin that has acts against liver fibrosis through 
inhibition of cytokine production[10].  
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MATERIALS AND METHODS 
Study design: An experimental animal based study 
Ethics approval: The experimental protocol was ap-
proved by the institutional animal ethics committee. 
(COPH/IAEC/PG/05/2018). 
Study location: Dr. V.V.P.F’s College of Pharmacy, Ah-
mednagar. 
Study duration: 28 days 
Animals: The healthy Albino Wistar rats of either sex, 
weighing between 180-250 g were taken for the study. 
They were housed under standard environmental con-
ditions of temperature (23±20c) humidity (55±5%) and 
12h light and 12h dark cycles. The animals were fed 
with standard pellet diet and water ad labium. The ex-
perimental protocol was approved by the institutional 
animal ethical committee as per the CPCSEA guidelines. 
Sample size: In each group n=6 
Drug and chemicals: Cisplatin was purchased from Het-
ero Healthcare Ltd, Diosgenin was purchased from Yar-
row Chem Products, Carbon tetrachloride was pur-
chased from Qualigens Fine chemicals and other rea-
gent were purchased from local market, all this chemi-
cals used in this studies were analytical grade. 
Dose Selection of Drug: Studies assessing Diosgenin for 
toxicity study have shown that the compound was usu-
ally well tolerated orally in doses of up to 500 mg/kg. 
The selected doses of Diosgenin 50, 100, 150 mg/kg 
body weight for the rats. They were given by oral route 
using oral gavage [11].  
Experimental protocol: Test compound formulation: 
Diosgenin was suspended in 0.5% w/v gum tragacanth 
in distilled water[1] . 
Induction of liver fibrosis by Carbon tetrachloride: The 
rats were subjected to intraperitoneally administration 
of 1ml/kg CCl4 mixed with an equal volume of olive oil, 
twice a week for 28 days. 
Methodology 
Experimental design: 1. CCl4 Induced liver fibrosis: 
The animals were divided into 5 groups of six animals in 
each group. 
Group I (control) -received distilled water (1ml/kg, p.o.) 
for 28 days 
Group II (Negative control) -received CCl4 (1 ml/kg i.p.) 
twice a week for 28 days 
Group III -received CCl4 (1 ml/kg i.p.) twice a week for 
28 days and Diosgenin (50 mg/kg p.o. daily) for 28 days 
Group IV-received CCl4 (1 ml/kg i.p.) twice a week for 
28 days and Diosgenin (100 mg/kg p.o. daily) for 28 
days 
 Group V- received CCl4 (1 ml/kg i.p.) twice a week for 
28 days and Diosgenin (150 mg/kg p.o. daily) for 28 
days [1, 12]. 
2. Cisplatin induced liver fibrosis:  
The animals were divided into 5 groups of six animals in 
each group.  
Group I (control)-received distilled water (1ml/kg, p.o.) 
for 28 days 
Group II (Negative control)-received cisplatin (3mg/kg 
i.p.)  at 0,1, 3 week for 4 weeks Group III-received 
cisplatin (3mg/kg i.p.)  at 0,1, 3 week for 4 weeks or 28 
daysand Diosgenin (50 mg/kg p.o, daily) for 28 days 
Group IV- received cisplatin (3mg/kg i.p.)  0, 1, 3 week 
for 4 weeks or 28 daysand Diosgenin (100 mg/kg p.o, 
daily) for 28 days 
 Group V- received cisplatin (3mg/kg i.p.)  0, 1, 3 week 
for 4 weeks or 28 daysand Diosgenin (150 mg/kg p.o, 
daily) for 28 days[13, 14]. 
Estimation of different parameters: After 28 days of 
both CCl4 and cisplatin induced liver fibrosis methods, 
the animals were kept to fasting overnight after the 
experimental period. They were anaesthetized with 
ether and blood was collected by puncturing retro-
orbital plexus and left at room temperature for 30 
minutes in dry test tubes without any disturbance. 
Then the blood samples were centrifuged for 10 
minutes at 3000 rpm to separate the serum. 
Biochemical parameter: At the end of treatment the 
serum was subjected to various biochemical tests to 
assess liver function such as aspartate transaminase 
(AST), alanine transaminase (ALT), alkaline phosphatase 
(ALP) and total bilirubin (TBL). The livers were homoge-
nized to estimate the level of hydroxyproline (HP).  
Morphological parameter: After completion of the 
experimental period the animals were sacrificed and 
abdomen was cut and open the liver was isolated and 
the weight of the liver was measured. 
Histo-pathological studies: Livers were dissected out 
and preserved in 10% formalin for Histopathological 
studies. Liver sections were stained with haematoxylin 
and eosin, the stained sections were observed under 
the microscope to estimate the extent of liver fibrosis. 
Statistical analysis: Results were expressed as the 
Mean ± standard error means (S.E.M). The comparison 
of data within groups was performed by the analysis of 
variance using ANOVA test. Significant difference be-
tween control and experimental groups was assessed 
by Dunnetts test. Statistical analysis was performed 
using INTA. A probability level of less than p<0.05 was 
considered significant. 
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RESULTS 
1. Effect on CCl4 induced liver fibrosis: At the end of 28 
days treatment of diosgenin in CCl4 induced liver fibro-
sis, the animals were subjected for biochemical investi-
gation. Serum level of AST, ALT, ALP, TB and HP were 
analyzed and shown in Table 1.  
T-50 = Diosgenin treated group (50 mg/kg) 
T-100 = Diosgenin treated group (100 mg/kg) 
T-150 = Diosgenin treated group (150 mg/kg) 
When the negative control group was compared with 
normal control group, there is significant (##p<0.01) 
increase in the serum level of AST, ALT, ALP, TB and 
level of Hydroxyproline. There is significant (** p<0.01) 
decrease in  the serum level of  AST, ALT, ALP, TB and 
level of HP in T-50 (CCl4 + Diosgenin 50 mg/kg p.o), T-
100 (CCl4 + Diosgenin 100 mg/kg p.o.) and T-150 (CCl4 
+ Diosgenin 150 mg/kg p.o.) group when compared 
with negative control group. 
Effect on liver weight in CCl4 induced liver fibrosis: 
When the liver weight of the negative control group 
was compared with control group, there is significant 
(##p<0.01) increase in the liver weight of negative con-
trol group due to ECM deposition or fatty infiltration. 
There is significant (** p<0.01) decrease in liver weight 
of T-50, T-100 and T-150 group when compared with 
negative control group. 
1.1 Histopathological examinations 
Histopathological examinations of the rat livers in 
CCl4 induced liver fibrosis:  
 
Figure 1: Group-I showed the structure of liver with 
normal hepatocytes surrounding the central vein and 
normal periportal area. 
               
Sr. 
No. 
Biochemical  
parameters 
Group 
Control 
Negative  
control 
T-50 T-100 T-150 
1 AST (U/ml) 
43               
± 1.065 
71.16## ±0.703 
66.33 **       
±  0.881 
53.33 **                
±1.453 
51.16 **            
± 0.872 
2 ALT (U/ml) 
35.5                    
± 2.012 
104##                        
 ± 1.701 
65.33**        
± 1.453 
45 **             
±1.826 
40.16 **                
± 2.414 
3 
ALP                      
(KA units/dl) 
7.85                     
± 0.260 
21.095##             
± 0.388 
17.038**         
± 0.429 
15.35**     
±0.277 
11.94 **               
±0.323 
4 TB (mg/dl) 
0.45                     
± 0.20 
1.52##                        
± 0.016 
0.57**             
± 0.026 
0.77 **                   
± 0.027 
0.65 **              
± 0.014 
5 HP (μg/g) 
50.66                   
± 2.515 
135##                         
± 3.270 
110 **              
± 2.887 
78.33 **           
± 2.108 
63.35 **              
± 1.667 
6 Liver weight (gm) 
4.5                      
±  0.089 
7.56##                         
± 0.079 
6.31 **                   
± 0.040 
6.18 **                 
± 0.044 
5.15 **                   
± 0.040 
Table 1. Effect of diosgenin treatment on different biochemical parameters and liver weight in CCl4 induced liver 
fibrosis: 
n=6, values are expressed as Mean ± SEM. Comparison were made as follows, # p<0.05, ## p<0.01 when compared 
with Normal control and *p<0.05, **p<0.01 when compared with negative control. Data was statistically analyzed 
by one way ANOVA followed by Dunnetts test.  
Ravine et al.  Protective effect of Diosgenin against Carbon tetrachloride and Cisplatin induced hepatotoxicity in 
rats. 
Figure 2: Group-II showed liver parenchyma with 
sheets of hepatocytes showing fatty change, areas of 
severe necrosis and periportal area shows dense fibro-
sis. 
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Figure 3: Group-III showed liver parenchyma with 
sheets of hepatocytes showing mild fatty infiltration. 
Figure 4: Group-IV showed liver parenchyma with 
sheets of hepatocytes showing mild necrosis. 
 
Figure 5: Group-V showed liver parenchyma with 
sheets of hepatocytes showing areas of, mild periportal 
fibrosis and sinusoids showed dilation. 
2. Effect on Cisplatin induced liver fibrosis: 
At the end of 28 days treatment of diosgenin in cispla-
tin induced liver fibrosis, serum level of AST, ALT, ALP, 
TB and HP were analyzed. 
There is significant (## p<0.01) increase in the serum 
level of AST, ALT, ALP, TB and level of hydroxyproline 
(HP) when the negative control group was compared 
with normal control group. There is significant (** 
p<0.01) decrease in  the serum level of  AST, ALT, ALP 
TB and level of HP in T-50 (Cisplatin + Diosgenin 50 mg/
kg p.o.), T-100 (Cisplatin + Diosgenin 100 mg/kg p.o.) 
and T-150 (Cisplatin + Diosgenin 150 mg/kg p.o.) group 
when compared with negative control group. 
Effect on liver weight in Cisplatin induced liver fibro-
sis: 
There is significant (##p<0.01) increase in the liver 
weight of negative control group (Cisplatin) When com-
                
Sr. 
No. 
Biochemical  
parameters 
Group 
Control Negative  
control 
T-50 T-100 T-150 
1 AST                   
(U/ml) 
44 ± 1.32 71.5##     
±0.763 
69.33 ** 
 ± 1.282 
52.33 **               
±1.453 
51.16 **     
± 0.872 
2 ALT                     
(U/ml) 
37.33                   
± 1.63 
103.16##                        
± 1.249 
62.33 **                
± 1.308 
46.66 **                 
± 1.619 
40.16 **                
± 1.301 
3 ALP                       
(KA units/dl) 
8.94                   
± 0.338 
32.43##                  
± 0.694 
24.77 **         
± 0.548 
19.422 **     
±0.306 
11.94 **               
±0.323 
4 TB                    
(mg/dl) 
0.43                  
± 0.017 
1.52##                        
± 0.014 
0.53 **             
± 0.095 
0.74 **                
± 0.016 
0.65 **              
± 0.010 
5 HP                     
(μg/g) 
49.66                   
± 2.404 
140##                         
± 2.887 
120 **              
± 2.884 
90 ** 
 ± 2.887 
80 **             
± 2.887 
6 Liver weight (gm) 4.53                    
±  0.09 
7.39##                            
± 0.09 
6.43 **                    
± 0.09 
6.30 **                  
± 0.057 
5.35 **                    
± 0.050 
n=6, values are expressed as Mean ± SEM. Comparison were made as follows, # p<0.05, ## p<0.01 when com-
pared with Normal control and* p<0.05, ** p<0.01 when compared with negative control. Data was statistically 
analyzed by one way ANOVA followed by Dunnetts test  
Table 2. Effect of diosgenin treatment on different biochemical parameters and liver weight in Cisplatin induced 
liver fibrosis  
Ravine et al.  Protective effect of Diosgenin against Carbon tetrachloride and Cisplatin induced hepatotoxicity in 
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pared with control group. There is significant (** 
p<0.01) decrease in liver weight of T-50, T-100 and T-
150 group when compared with negative control 
group.  
2.1 Histopathological examination 
Histopathological examination of the rat livers in cis-
platin induced liver fibrosis:    
 
 
 
 
 
 
 
Figure 6: group-I showed the structure of liver with 
normal periportal area 
 
Figure 7: Group-II showed dense ECM infiltration, in-
flammation and periportal fibrosis 
 
 
Figure 8: Group-III showed mild ECM infiltration. 
Figure 9: Group- IV The section from group-IV showed 
liver parenchyma with sheets of hepatocytes showing 
mild inflammation. 
Figure 10: Group-V showed, tissue is free from inflam-
matory cells. 
DISCUSSION 
Many herbal drugs possess hepatoprotective effect 
hence can be used for the management of various liver 
diseases. The CCl4 possess hepatotoxic effect in the 
experimental animals. The enzyme cytochrome P450 
biotransformed CCl4 and produce the trichloromethyl 
free radicals, which cause lipid peroxidation of lipids 
membrane and peroxidative degradation in the adipose 
tissue resulting in fatty or ECM infiltration of the 
hepatocytes. All these events culminate in loss of integ-
rity of cell membrane and damage of hepatic cells [15]. 
Free radical generation causes oxidative damage due to 
hepatotoxic effect of CCl4.In hepatotoxicity, cause liver 
damage due to serum enzymes leak into blood stream. 
The elevated levels of biomarker (AST, ALT, ALP), TBL 
and HP are indications of hepatotoxicity in CCl4induced 
rats. 
In our study, a repeated administration of CCl4 for four 
weeks (twice a week) to the experimental animals led 
to progressive deterioration of liver structure, with a 
subsequent liver fibrosis [7]. In the present study, the 
transaminase (AST, ALT, ALP) level increased by CCl4 
treatment was significantly (p<0.01) reduced by dios-
genin treatment T-50, T-100 and T150. The total biliru-
bin and HP level was also restored to the near normal 
level upon CCl4 intoxication by the diosgenin treat-
Ravine et al.  Protective effect of Diosgenin against Carbon tetrachloride and Cisplatin induced hepatotoxicity in 
rats. 
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ment. These findings were further supported by histo-
pathological studies, which clearly indicated that the 
hepatic fibrosis occurred in negative control group and 
increased liver weight and HP content were also seen 
in negative control group. HP content is good marker of 
liver fibrosis. The increased weight of liver by CCl4 was 
restored by diosgenin (T-150) up to the near normal 
significantly (p<0.01). This revels that diosgenin treat-
ment prevented the ECM deposition in the liver cells 
and indicating hepatoprotective and antifibrotic action. 
The comparative Histopathological study of the liver 
from different groups of rat corroborated the hepato-
protective efficacy of the diosgenin. Various pathologi-
cal changes like steatosis, fatty change, areas of severe 
necrosis, periportal inflammatory infiltrate and peri-
portal fibrosis, associated with liver fibrosis were pre-
vented to moderate extent in treatment group.  
High doses of cisplatin have been known to produce 
hepatotoxicity [16]. Hepatotoxicity induced by cisplatin 
is recognized by the alteration of the biochemical, his-
tological, and molecular parameters. As ALT exists 
mainly in the liver cell cytoplasm, it is one of the most 
sensitive parameters for liver cell function test as rec-
ommended by WHO. The result of our study showed 
that activities of serum enzymes (ALT, AST, and ALP) in 
negative control group increased in comparison with 
the control group. ALT, AST, and ALP enzymes levels 
increase in serum confirmed hepatocytes cell mem-
brane damage and enzymes leak from the hepatocytes 
[12]. Our result showed that cisplatin makes dose-
dependent changes in liver structure: some of these 
changes impair hepatocytes arrangement, liver lobula-
tion, and necrosis. This study also confirmed that addi-
tion of some antioxidant foods may have preventive 
effects on cisplatin induced hepatotoxicity. The differ-
ence in weight of animals after the experiment showed 
a significant difference between normal control and 
negative control group.  
In the present study, administration of Cisplatin for 0, 
1, 3 weeks to the experimental animals cause impair-
ment of liver architecture, with a progression of liver 
fibrosis [7]. In the present study, the transaminase 
(AST, ALT, ALP) level increased by Cisplatin treatment 
was significantly (p<0.01) decrease by diosgenin treat-
ment groups. The increased weight of liver by Cisplatin 
was restored by diosgenin T-150 up to the near normal 
significantly (p<0.01) after28 days. Result in diosgenin 
treatment prevented cisplatin induced liver fibrosis. In 
the  Histopathological study of the liver from different 
groups of rat normal control group shows normal he-
patic cells and, where as administration of Cisplatin in 
negative control group showed portal fibrosis and 
treated group showed mild ECM infiltration.  
CONCLUSION 
In conclusion, there have been considerable advances 
in the understanding of the mechanisms that underlie 
hepatic fibrogenesis. The central event in fibrogenesis 
appears to be the activation of HSCs, which is a com-
plex process. Taking into consideration the results ob-
tained in the present investigation, it can be concluded 
that, Diosgenin treatment exerted significant hepato-
protective effect in laboratory animals by inhibiting 
ECM deposition and HSCs activation.  
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